DURHAM, N.C. and ZURICH, Switzerland, Jan. 12, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced it has entered into an agreement with the newly formed, independently owned and operated DERMACYTE Switzerland Ltd. (DSL) of Zurich for the sale of DERMACYTE products. Per the terms of the agreement, DSL has exclusive rights to sell and distribute Oxygen Biotherapeutics' DERMACYTE ® skin care products that it purchases throughout the European Union, Switzerland and Russia. The agreement also grants DSL the option to add South America as an exclusive territory if purchase volume milestones are achieved.
Oxygen Biotherapeutics Signs Agreement To Sell DERMACYTE Products To Swiss Sales And Distribution Company
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.